Terumo (OTCMKTS:TRUMY) Stock Moved Up to Strong-Buy by Zacks Research

Terumo (OTCMKTS:TRUMY) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Tuesday, Zacks reports.

Separately, Nomura upgraded shares of Terumo from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Two equities research analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat, the stock has an average rating of “Strong Buy”.

Terumo Price Performance

TRUMY opened at $14.15 on Tuesday. The company’s 50-day simple moving average is $15.11 and its two-hundred day simple moving average is $14.22. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.37 and a current ratio of 2.19. The stock has a market capitalization of $20.87 billion, a P/E ratio of 19.93 and a beta of 0.77. Terumo has a 52-week low of $12.08 and a 52-week high of $17.81.

Terumo (OTCMKTS:TRUMY) last announced its quarterly earnings results on Friday, August 7th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.13. Terumo had a net margin of 13.83% and a return on equity of 10.44%. The firm had revenue of $1.97 billion during the quarter, compared to analyst estimates of $1.84 billion. As a group, analysts predict that Terumo will post 0.86 EPS for the current year.

About Terumo

Terumo Corporation is a Japan-based medical technology company that develops, manufactures and sells products used in hospitals, clinics and other healthcare settings. Founded in 1921 by a group of Japanese medical doctors, the company initially produced clinical thermometers and has since expanded into a global provider of medical devices and related services.

Terumo’s principal businesses include cardiac and vascular products, blood and cell technologies, and general hospital solutions.